Status:
COMPLETED
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Lead Sponsor:
Alexion Pharmaceuticals, Inc.
Conditions:
C3 Glomerulopathy
C3 Glomerulonephritis
Eligibility:
All Genders
17-65 years
Phase:
PHASE2
Brief Summary
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who ...
Eligibility Criteria
Inclusion
- Key
- Had biopsy-confirmed primary C3G
- Had clinical evidence of ongoing disease based on significant proteinuria, attributable to C3G disease in the opinion of the Principal Investigator (PI), and present prior to study entry and confirmed during Screening
- Was willing to comply with vaccination requirements.
- Key
Exclusion
- Had a history or presence of any clinically relevant co-morbidities that would make the participant inappropriate for the study
- Had ever received danicopan
- Had more than 50% fibrosis or more than 50% of glomeruli with cellular crescents on the pre-treatment renal biopsy
- Had an estimated glomerular filtration rate \<30 milliliters/minute/1.73 meters squared at the time of screening or at any time over the preceding 4 weeks
- Was a renal transplant recipient or receiving renal replacement therapy
- Had a history of a major organ transplant or hematopoietic stem cell/marrow transplant
- Had evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary
- Had other renal diseases that would interfere with interpretation of the study
- Had been diagnosed with or showed evidence of hepatobiliary cholestasis
- Females who were pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration
- Had a history of febrile illness, a body temperature \>38°Celsius, or other evidence of a clinically significant active infection, within 14 days prior to study drug administration
- Had evidence of human immunodeficiency virus, hepatitis B infection, or active hepatitis C infection at Screening
- Had laboratory abnormalities at screening that, in the opinion of the PI, would make the participant inappropriate for the study
Key Trial Info
Start Date :
June 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2020
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03369236
Start Date
June 12 2018
End Date
December 18 2020
Last Update
October 14 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Study Site
Aurora, Colorado, United States, 80045
2
Clinical Study Site
Lawrenceville, Georgia, United States, 30046
3
Clinical Study Site
Iowa City, Iowa, United States, 52242
4
Clinical Study Site
Baltimore, Maryland, United States, 21205